Skip to main content
Start of content
Start of content

e-4824 (Health)

E-petition
Initiated by Serena Liu from Calgary, Alberta

Original language of petition: English

Petition to the House of Commons

Whereas:
  • Lung cancer has the highest mortality rate of all cancers in Canada and is increasingly diagnosed in non-smokers with no other risk factors;
  • Patients are increasingly diagnosed at the late stages of cancer and thus are limited in treatment plans and are sometime given only weeks-months left to live;
  • Delays to accessing new treatments do not help, particularly as lung cancer research receives limited funding compared to other cancers in Canada; and
  • We need your support to ensure that all Canadians have access to the best available treatments. Canadians are faced with significant barriers in accessing their prescribed cancer treatments: which province they live in, paying out-of-pocket costs or travel to other countries to receive care when Canada is so behind on approving the newest protocols approved by the FDA.
We, the undersigned, residents and citizens of Canada, call upon the House of Commons to:
1. Support patient access and funding of Osimertinib and chemotherapy together as combination therapy on disease progression;
2. Support access and funding of Amivantamab plus chemotherapy with and without Lazertinib as a second line treatment option.
3. Support the approval and funding of new treatments and clinical trials for EGFR lung cancer through the drug review and reimbursement processes at the federal and provincial levels; and
4. Work with other stakeholders, such as provincial cancer agencies, health care providers, patient groups, and drug manufacturers, to improve access and affordability of cancer drugs for all Canadians.
Open for signature
February 29, 2024, at 10:45 a.m. (EDT)
Closed for signature
May 29, 2024, at 10:45 a.m. (EDT)
Photo - Kevin Waugh
Saskatoon—Grasswood
Conservative Caucus
Saskatchewan